We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Cirrus Pharmaceuticals to Invest in cGMP Manufacturing Suite in US

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Cirrus Pharmaceuticals to Invest in cGMP Manufacturing Suite in US"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Cirrus Pharmaceuticals has announced that it will be investing in a flexible cGMP suite in its facility in RTP, North Carolina.

Ninad Deshpanday, President of R&D at Kemwell said, “With this investment, we are bringing our customers a new service from our US facility. We will offer our clients cGMP manufacturing services for many dosage forms including inhalation, liquids, topicals and oral solids. Our clients will be able to use this service to go to clinic faster. We have completed the design phase and expect the suite to be ready to service customers by April 2015.”

Today, Kemwell’s R&D division employs over 175 scientists worldwide and provides services ranging from formulation development, analytical development and validation to clinical trial manufacturing.

The team has experience working on early stage development programs for NCEs, ANDAs, 505(b)(2) and product life cycle management projects for various customers across the world, including virtual, small and big pharma.

With the addition of the cGMP suite, Cirrus will be able to extend its offerings in the US from contract development to manufacturing.